{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:44:45Z","timestamp":1787672685176,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82200417"],"award-info":[{"award-number":["82200417"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Projects in Guangzhou","award":["2023A04J1280"],"award-info":[{"award-number":["2023A04J1280"]}]},{"name":"Talent introduction funding project of the First Affiliated Hospital of Jinan University","award":["808026"],"award-info":[{"award-number":["808026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-024-02520-8","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T12:32:28Z","timestamp":1733315548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["SGLT2 inhibitor downregulates ANGPTL4 to mitigate pathological aging of cardiomyocytes induced by type 2 diabetes"],"prefix":"10.1186","volume":"23","author":[{"given":"Yun","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Duo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"issue":"4","key":"2520_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41569-021-00624-2","volume":"19","author":"M Mehdizadeh","year":"2022","unstructured":"Mehdizadeh M, Aguilar M, Thorin E, Ferbeyre G, Nattel S. The role of cellular senescence in cardiac disease: basic biology and clinical relevance. Nat Rev Cardiol. 2022;19(4):250\u201364.","journal-title":"Nat Rev Cardiol"},{"issue":"155","key":"2520_CR2","doi-asserted-by":"publisher","first-page":"190102","DOI":"10.1183\/16000617.0102-2019","volume":"29","author":"MJ Hughes","year":"2020","unstructured":"Hughes MJ, McGettrick HM, Sapey E. Shared mechanisms of multimorbidity in COPD, atherosclerosis and type-2 diabetes: the neutrophil as a potential inflammatory target. Eur Respir Rev. 2020;29(155):190102.","journal-title":"Eur Respir Rev"},{"key":"2520_CR3","doi-asserted-by":"publisher","first-page":"716517","DOI":"10.3389\/fphar.2021.716517","volume":"12","author":"SM Henson","year":"2021","unstructured":"Henson SM, Aksentijevic D. Senescence and type 2 diabetic cardiomyopathy: how young can you die of old age. Front Pharmacol. 2021;12:716517.","journal-title":"Front Pharmacol"},{"issue":"4","key":"2520_CR4","first-page":"279","volume":"14","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zheng Y, Wang S, et al. Single-nucleus transcriptomics reveals a gatekeeper role for FOXP1 in primate cardiac aging. Protein Cell. 2023;14(4):279\u201393.","journal-title":"Protein Cell"},{"issue":"5","key":"2520_CR5","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/cvr\/cvab161","volume":"118","author":"MS Chen","year":"2022","unstructured":"Chen MS, Lee RT, Garbern JC. Senescence mechanisms and targets in the heart. Cardiovasc Res. 2022;118(5):1173\u201387.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"2520_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cell.2014.10.039","volume":"159","author":"BK Kennedy","year":"2014","unstructured":"Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell. 2014;159(4):709\u201313.","journal-title":"Cell"},{"issue":"9","key":"2520_CR7","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/nm.2014","volume":"15","author":"T Minamino","year":"2009","unstructured":"Minamino T, Orimo M, Shimizu I, et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat Med. 2009;15(9):1082\u20137.","journal-title":"Nat Med"},{"issue":"3","key":"2520_CR8","doi-asserted-by":"publisher","first-page":"e12746","DOI":"10.1111\/acel.12746","volume":"17","author":"L Fontana","year":"2018","unstructured":"Fontana L, Mitchell SE, Wang B, et al. The effects of graded caloric restriction: XII. Comparison of mouse to human impact on cellular senescence in the colon. Aging Cell. 2018;17(3):e12746.","journal-title":"Aging Cell"},{"key":"2520_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.nbd.2018.07.021","volume":"126","author":"S Guo","year":"2019","unstructured":"Guo S, Deng W, Xing C, Zhou Y, Ning M, Lo EH. Effects of aging, hypertension and diabetes on the mouse brain and heart vasculomes. Neurobiol Dis. 2019;126:117\u201323.","journal-title":"Neurobiol Dis"},{"key":"2520_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.exger.2018.12.019","volume":"119","author":"X Zhang","year":"2019","unstructured":"Zhang X, Liu C, Liu C, Wang Y, Zhang W, Xing Y. Trimetazidine and l\u2013carnitine prevent heart aging and cardiac metabolic impairment in rats via regulating cardiac metabolic substrates. Exp Gerontol. 2019;119:120\u20137.","journal-title":"Exp Gerontol"},{"issue":"8","key":"2520_CR11","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1161\/CIRCRESAHA.118.314665","volume":"124","author":"WH Dillmann","year":"2019","unstructured":"Dillmann WH. Diabetic cardiomyopathy. Circ Res. 2019;124(8):1160\u20132.","journal-title":"Circ Res"},{"issue":"4","key":"2520_CR12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624\u201338.","journal-title":"Circ Res"},{"issue":"5","key":"2520_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","volume":"138","author":"K R\u00e5dholm","year":"2018","unstructured":"R\u00e5dholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes Mellitus: results from the CANVAS program. Circulation. 2018;138(5):458\u201368.","journal-title":"Circulation"},{"issue":"7","key":"2520_CR14","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","volume":"59","author":"N Sattar","year":"2016","unstructured":"Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms. Diabetologia. 2016;59(7):1333\u20139.","journal-title":"Diabetologia"},{"key":"2520_CR15","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.7573\/dic.2019-11-3","volume":"9","author":"E Kaplinsky","year":"2020","unstructured":"Kaplinsky E. DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs Context. 2020;9:2019\u201311.","journal-title":"Drugs Context"},{"issue":"4","key":"2520_CR16","doi-asserted-by":"publisher","first-page":"e13596","DOI":"10.1111\/acel.13596","volume":"21","author":"AS Kulkarni","year":"2022","unstructured":"Kulkarni AS, Aleksic S, Berger DM, Sierra F, Kuchel GA, Barzilai N. Geroscience-guided repurposing of FDA-approved drugs to target aging: a proposed process and prioritization. Aging Cell. 2022;21(4):e13596.","journal-title":"Aging Cell"},{"issue":"1","key":"2520_CR17","doi-asserted-by":"publisher","first-page":"14459","DOI":"10.1038\/s41598-020-71449-1","volume":"10","author":"R Hasan","year":"2020","unstructured":"Hasan R, Lasker S, Hasan A, et al. Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways. Sci Rep. 2020;10(1):14459.","journal-title":"Sci Rep"},{"key":"2520_CR18","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.2147\/DMSO.S243170","volume":"13","author":"AR Ndibalema","year":"2020","unstructured":"Ndibalema AR, Kabuye D, Wen S, Li L, Li X, Fan Q. Empagliflozin protects against proximal renal tubular cell Injury Induced by high glucose via regulation of Hypoxia-Inducible factor 1-Alpha. Diabetes Metab Syndr Obes. 2020;13:1953\u201367.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"2520_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"2520_CR20","doi-asserted-by":"publisher","first-page":"596","DOI":"10.4239\/wjd.v11.i12.596","volume":"11","author":"VV Klimontov","year":"2020","unstructured":"Klimontov VV, Korbut AI, Taskaeva IS, et al. Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db\/db diabetic mice. World J Diabetes. 2020;11(12):596\u2013610.","journal-title":"World J Diabetes"},{"key":"2520_CR21","doi-asserted-by":"publisher","first-page":"26428","DOI":"10.1038\/srep26428","volume":"6","author":"LA Gallo","year":"2016","unstructured":"Gallo LA, Ward MS, Fotheringham AK, et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db\/db mice. Sci Rep. 2016;6:26428.","journal-title":"Sci Rep"},{"issue":"7","key":"2520_CR22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"key":"2520_CR23","doi-asserted-by":"publisher","first-page":"104215","DOI":"10.1016\/j.ebiom.2022.104215","volume":"83","author":"YM Gao","year":"2022","unstructured":"Gao YM, Feng ST, Wen Y, Tang TT, Wang B, Liu BC. Cardiorenal protection of SGLT2 inhibitors-perspectives from metabolic reprogramming. EBioMedicine. 2022;83:104215.","journal-title":"EBioMedicine"},{"issue":"8","key":"2520_CR24","doi-asserted-by":"publisher","first-page":"bqab079","DOI":"10.1210\/endocr\/bqab079","volume":"162","author":"C Hoong","year":"2021","unstructured":"Hoong C, Chua M. SGLT2 inhibitors as calorie restriction mimetics: insights on Longevity pathways and age-related diseases. Endocrinology. 2021;162(8):bqab079.","journal-title":"Endocrinology"},{"key":"2520_CR25","doi-asserted-by":"publisher","first-page":"1163288","DOI":"10.3389\/fimmu.2023.1163288","volume":"14","author":"A Mazzieri","year":"2023","unstructured":"Mazzieri A, Basta G, Calafiore R, Luca G. GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway. Front Immunol. 2023;14:1163288.","journal-title":"Front Immunol"},{"issue":"7415","key":"2520_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature11432","volume":"489","author":"JA Mattison","year":"2012","unstructured":"Mattison JA, Roth GS, Beasley TM, et al. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature. 2012;489(7415):318\u201321.","journal-title":"Nature"},{"issue":"9","key":"2520_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S2213-8587(19)30151-2","volume":"7","author":"WE Kraus","year":"2019","unstructured":"Kraus WE, Bhapkar M, Huffman KM, et al. 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(9):673\u201383.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2520_CR28","doi-asserted-by":"crossref","unstructured":"Katsuumi G, Shimizu I, Suda M et al. SGLT2 inhibition eliminates senescent cells and alleviates pathological aging. Nat Aging. 2024.","DOI":"10.1038\/s43587-024-00642-y"},{"key":"2520_CR29","doi-asserted-by":"crossref","unstructured":"Long J, Ren Z, Duan Y et al. Empagliflozin rescues lifespan and liver senescence in naturally aged mice. Geroscience. 2024.","DOI":"10.1007\/s11357-024-01250-9"},{"issue":"12","key":"2520_CR30","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","volume":"374","author":"NO Stitziel","year":"2016","unstructured":"Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators, Stitziel NO, et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016;374(12):1134\u201344.","journal-title":"N Engl J Med"},{"issue":"12","key":"2520_CR31","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","volume":"374","author":"FE Dewey","year":"2016","unstructured":"Dewey FE, Gusarova V, O\u2019Dushlaine C, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123\u201333.","journal-title":"N Engl J Med"},{"issue":"8","key":"2520_CR32","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.molmed.2019.05.010","volume":"25","author":"B Aryal","year":"2019","unstructured":"Aryal B, Price NL, Suarez Y, Fern\u00e1ndez-Hernando C. ANGPTL4 in metabolic and cardiovascular disease. Trends Mol Med. 2019;25(8):723\u201334.","journal-title":"Trends Mol Med"},{"issue":"9","key":"2520_CR33","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","volume":"38","author":"D Basu","year":"2018","unstructured":"Basu D, Huggins LA, Scerbo D, et al. Mechanism of increased LDL (low-Density lipoprotein) and decreased triglycerides with SGLT2 (sodium-Glucose cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol. 2018;38(9):2207\u201316.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2520_CR34","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1194\/jlr.M047860","volume":"55","author":"T Kuo","year":"2014","unstructured":"Kuo T, Chen TC, Yan S, et al. Repression of glucocorticoid-stimulated angiopoietin-like 4 gene transcription by insulin. J Lipid Res. 2014;55(5):919\u201328.","journal-title":"J Lipid Res"},{"key":"2520_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cellsig.2017.12.005","volume":"43","author":"MP Sajan","year":"2018","unstructured":"Sajan MP, Lee MC, Foufelle F, Sajan J, Cleland C, Farese RV. Coordinated regulation of hepatic FoxO1, PGC-1\u03b1 and SREBP-1c facilitates insulin action and resistance. Cell Signal. 2018;43:62\u201370.","journal-title":"Cell Signal"},{"issue":"1","key":"2520_CR36","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/jcsm.12814","volume":"13","author":"R Bamba","year":"2022","unstructured":"Bamba R, Okamura T, Hashimoto Y, et al. Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db\/db mice. J Cachexia Sarcopenia Muscle. 2022;13(1):574\u201388.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"11","key":"2520_CR37","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/ajh\/hpae092","volume":"37","author":"V Vallon","year":"2024","unstructured":"Vallon V. State-of-the-Art-Review: mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens. 2024;37(11):841\u201352.","journal-title":"Am J Hypertens"},{"issue":"4","key":"2520_CR38","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/db16-0733","volume":"66","author":"M Joubert","year":"2017","unstructured":"Joubert M, Jagu B, Montaigne D, et al. The sodium-glucose cotransporter 2 inhibitor Dapagliflozin prevents cardiomyopathy in a Diabetic Lipodystrophic Mouse Model. Diabetes. 2017;66(4):1030\u201340.","journal-title":"Diabetes"},{"issue":"3","key":"2520_CR39","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI60329","volume":"122","author":"PK Battiprolu","year":"2012","unstructured":"Battiprolu PK, Hojayev B, Jiang N, et al. Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice. J Clin Invest. 2012;122(3):1109\u201318.","journal-title":"J Clin Invest"},{"issue":"1","key":"2520_CR40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1161\/CIRCHEARTFAILURE.114.001457","volume":"8","author":"Y Qi","year":"2015","unstructured":"Qi Y, Zhu Q, Zhang K, et al. Activation of Foxo1 by insulin resistance promotes cardiac dysfunction and \u03b2-myosin heavy chain gene expression. Circ Heart Fail. 2015;8(1):198\u2013208.","journal-title":"Circ Heart Fail"},{"key":"2520_CR41","doi-asserted-by":"publisher","first-page":"12313","DOI":"10.1038\/ncomms12313","volume":"7","author":"B Aryal","year":"2016","unstructured":"Aryal B, Rotllan N, Araldi E, et al. ANGPTL4 deficiency in haematopoietic cells promotes monocyte expansion and atherosclerosis progression. Nat Commun. 2016;7:12313.","journal-title":"Nat Commun"},{"issue":"3","key":"2520_CR42","doi-asserted-by":"publisher","first-page":"oeae035","DOI":"10.1093\/ehjopen\/oeae035","volume":"4","author":"F Landfors","year":"2024","unstructured":"Landfors F, Henneman P, Chorell E, Nilsson SK, Kersten S. Drug-target mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease risk. Eur Heart J Open. 2024;4(3):oeae035.","journal-title":"Eur Heart J Open"},{"key":"2520_CR43","doi-asserted-by":"publisher","first-page":"705154","DOI":"10.3389\/fendo.2021.705154","volume":"12","author":"L Dai","year":"2021","unstructured":"Dai L, Xie Y, Zhang W, et al. Weighted gene co-expression network analysis identifies ANGPTL4 as a key regulator in diabetic cardiomyopathy via FAK\/SIRT3\/ROS pathway in cardiomyocyte. Front Endocrinol (Lausanne). 2021;12:705154.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02520-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02520-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02520-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T14:02:57Z","timestamp":1733320977000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02520-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2520"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02520-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jinan University Experimental Animal Welfare Ethics Committee approved all animal experiments in this study (IACUC-20220512-06).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"430"}}